<!-- eslint-disable -->
<template>
  <div class="max-w-3xl mx-auto my-16">
    <h1 class="text-4xl font-extrabold mb-8">
      Modak thanks pharma’s Covid-19 efforts
    </h1>
    <v-img src="img/backgrounds/Medical_Research.jpg" height="360"></v-img>
    <p class="my-8 text-xl text-gray-900">
      In these uncertain times of increasing pandemic, many pharmaceutical
      companies across the globe have been fighting the battle against Covid-19
      on the frontlines. They are making efforts to combat virus in multiple
      areas, such as research and development of vaccine candidates, clinical
      trials, develop therapies and improve diagnostic testing capabilities. For
      all this and more, we at Modak want to offer our heartfelt thanks to
      pharmaceutical firms! We want to assure that Modak will be there to
      support its customers and partners.
    </p>
    <p class="my-8 text-xl text-gray-900">
      As pharmaceutical firms, including start-ups, collaborate to tackle
      Covid-19, there have been a few developments in many areas. Many companies
      are pertaining to the virus. While some are sharing their technologies,
      others are using their expertise and earlier studies. Here are a few
      developments around the world in the past few months in the fight against
      Covid-19 in breif.
    </p>
    <p class="my-8 text-xl text-gray-900">
      The below graph shows how far various companies have reached so far in
      their efforts to find a solution for this global pandemic. The bars
      represent the number of companies at various stages.
    </p>
    <v-img
      src="img/backgrounds/companies_vaccine_development_chart.png"
    ></v-img>
    <span class="text-center mx-auto"
      >Figure: companies at various stages in vaccine development</span
    >
    <h2 class="text-2xl font-bold mt-8">
      Recent developments at various companies
    </h2>
    <p class="mt-4 text-xl text-gray-900">
      <strong>Pfizer</strong> has announced a five-point plan to help scientists develop treatments and vaccines and has given a call to the pharmaceutical industry to collaborate with the company in sharing tools, marshalling people, offering manufacturing capabilities and improving rapid response. Pfizer is developing and distributing BioNTech SE’s COVID-19 vaccine candidate.
    </p>
    <p class="my-8 text-xl text-gray-900">
      <strong>GlaxoSmithKline</strong>  has said that the University of Queensland would have access to its adjuvant platform technology, which is believed to both strengthen the response of a vaccine and limit the amount of vaccine needed per dose. The company has also given access to its adjuvant technology to Clover Biopharmaceuticals Inc., a Chinese biotechnology company, for its vaccine candidate, COVID-19 S-Trimer, in preclinical studies.
    </p>
    <p class="my-8 text-xl text-gray-900">
      <strong>Johnson & Johnson</strong>  is working with Biomedical Advanced Research and Development Authority (BARDA) to test its vaccine candidate, with each organization providing $1 billion for research and development. The company has also started preclinical testing on multiple candidates in collaboration with Beth Israel Deaconess Medical Centre (BIDMC) in Boston, and has identified a lead vaccine candidate. The company, in partnership with BARDA, is also working on to screen existing antiviral medications that may be effective against COVID-19.
    </p>
    <p class="my-8 text-xl text-gray-900">
      <strong>Roche</strong>, in collaboration with BARDA, is evaluating its drug Actemra as a treatment for COVID-19 patients who have been hospitalized with severe pneumonia. Roche expects to begin enrolling around 330 patients in early April. The company plans to examine patient mortality and need for mechanical ventilation or an intensive care unit stay among others.
    </p>
    <p class="my-8 text-xl text-gray-900">
      <strong>CytoDyn</strong>, a preclinical biotechnology company based in Vancouver, has been approved to test the efficacy and safety of its experimental drug, Leronlimab, in Covid-19 patients. It’s being proposed as a treatment for mild-to-moderate respiratory complications that occur in patients with the disease.
    </p>
    <p class="my-8 text-xl text-gray-900">
      <strong>AstraZeneca</strong>  has been working on to enhance its diagnostic testing capabilities and collaborating with governments on existing screening programmes to augment testing.
    </p>
    <p class="my-8 text-xl text-gray-900">
      <strong>AbbVie</strong>  has been partnering with authorities across the globe to determine the effectiveness of HIV drugs in treating Covid-19.
    </p>
    <p class="text-xl text-gray-900">
      <strong>Gilead</strong>  is conducting a randomized, controlled clinical trial in Wuhan, testing for its drug remdesivir as a treatment for mild-to-moderate forms of pneumonia in people with the virus.
    </p>
    <p class="text-xl text-gray-900">
      <strong>Heat Biologics</strong> has announced that it is developing a vaccine for the novel coronavirus with Miller School of Medicine at the University of Miami.
    </p>
    <p class="text-xl text-gray-900">
      <strong>Novavax</strong>, a preclinical biotechnology company, announced Feb. 26 it had several vaccine candidates in preclinical animal studies, and it is planning to initiate a Phase I clinical study by June.
    </p>
    <p class="text-xl text-gray-900">
      <strong>Moderna</strong>  has received funding from CEPI to develop an mRNA vaccine against COVID-19.
    </p>
    <p class="text-xl text-gray-900">
      <strong>Vir Biotechnology</strong>  has been collaborating with Shanghai-based WuXi Biologics to test monoclonal antibodies as a treatment for COVID-19. They will work together to develop antibodies to treat SARS-CoV-2.
    </p>
    <p class="text-xl text-gray-900">
      <strong>Regeneron</strong> is working on developing monoclonal antibodies as treatments for COVID-19. The company aims to have hundreds of thousands of prophylactic doses ready for human testing by end of August.
    </p>
    <p class="text-xl text-gray-900">
      <strong>Sanofi</strong> is working with BARDA to test a preclinical vaccine candidate for severe acute respiratory syndrome (SARS) for COVID-19 using its recombinant DNA platform.
    </p>
    <p class="text-xl text-gray-900">
      <strong>Vaxart</strong> was one of the first companies to announce plans to develop a vaccine. It has announced that Emergent Bio Solutions would help develop and manufacture its oral vaccine candidate. The company plans to start a Phase 1 clinical trial in the U.S. in late 2020.
    </p>
    <p class="text-xl text-gray-900">
      <strong>Inovio</strong> develops immunotherapies and vaccines, but hasn’t yet had a product approved for treatment. The company plans to begin clinical trials with 30 participants in April in the U.S.
    </p>
  </div>
</template>
<!-- eslint-disable -->

<script>
export default {
  name: "PharmaFirms",
};
</script>

<style lang="scss" scoped>
</style>